EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyse

Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis

Christos-Nikiforos Balapanidis-Parisis iD, Anastasios Stefanou iD, Evangelos Ntouros iD, Andreas S Lappas iD, Vasilios-Panteleimon Bozikas iD, Myrto T Samara

Annals of Pharmacotherapy · 20.11.2026

DOI: 10.1177/10600280261500503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 20.11.2026. Verfasst von Christos-Nikiforos Balapanidis-Parisis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece. Die Arbeit nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Amitriptyline remains in use among older adults despite safety concerns. This diagnosis-independent systematic review and meta-analysis evaluated amitriptyline safety and tolerability versus active comparators or placebo in older adults. Data Sources: We searched MEDLINE, CENTRAL, Embase, PsycINFO, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) through September 30, 2026. Study Selection and Data Extraction: Eligible randomized controlled trials (RCTs) compared amitriptyline with placebo or active comparators in older adults (participants aged ≥60 years or study populations with mean age ≥70 years). Primary outcomes included serious adverse events (SAEs), dizziness, and acute cognitive adverse outcomes. Secondary outcomes included 60 safety, tolerability, and acceptability outcomes. Risk ratios (RRs) and mean differences were calculated. Random-effects meta-analyses were conducted separately versus placebo and active comparators on an intention-to-treat basis. Subgroup and sensitivity analyses explored robustness. Data Synthesis: In total, 32 RCTs (2243 participants) were included. Versus active comparators, that is, antidepressants or mood stabilizers, amitriptyline did not increase serious adverse events (SAEs) (RR = 1.13; 95% CI, 0.66-1.93), but increased dizziness (RR = 1.38; 95% CI, 1.06-1.79). Regarding cognition, no difference was found for disturbance in attention (RR = 2.44; 95% CI, 0.89-6.71) or confusional state (RR = 1.76; 95% CI, 0.42-7.35); disorientation was reported in 1 trial. Amitriptyline was associated with increased risk of any adverse event, withdrawals due to adverse events, anticholinergic and sedative adverse events, and weight gain. Placebo-controlled data were sparse, with no SAEs reported. Limitations included short trials, sparse adverse event reporting, and restricted eligibility. Relevance to Patient Care and Clinical Practice: Amitriptyline’s main limitation in older adults may be tolerability rather than excess serious harm. It should not be a first-line option, but may remain reasonable for selected patients with clear therapeutic rationale.

Conclusion

Compared with active comparators, amitriptyline showed no detectable excess in SAEs but increased dizziness and anticholinergic and sedative adverse events.

Schlagwörter

Stichwörter der Autor:innen

amitriptylineelderlymeta-analysisolder adultssafetysystematic reviewtolerability

Autor:innen und Institutionen

  • Second Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.
  • Department of Psychiatry, School of Medicine, University of Thessaly, Larissa, Greece.
  • Department of Geriatric Psychiatry, Aneurin Bevan University Health Board, Newport, UK.

ORCID-Profile: Christos-Nikiforos Balapanidis-Parisis, Anastasios Stefanou, Evangelos Ntouros, Andreas S Lappas, Vasilios-Panteleimon Bozikas

Zitieren

APA

Balapanidis-Parisis, C. N., Stefanou, A., Ntouros, E., Lappas, A. S., Bozikas, V. P., & Samara, M. T. (2026). Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261500503

Vancouver

Balapanidis-Parisis CN, Stefanou A, Ntouros E, Lappas AS, Bozikas VP, Samara MT. Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261500503

BibTeX
@article{BalapanidisParisis2026,
  author = {Balapanidis-Parisis, Christos-Nikiforos and Stefanou, Anastasios and Ntouros, Evangelos and Lappas, Andreas S and Bozikas, Vasilios-Panteleimon and Samara, Myrto T},
  title = {Examining the Safety Profile of Amitriptyline Versus Placebo and Active Comparators in the Elderly: A Systematic Review and Meta-Analysis},
  journal = {Annals of Pharmacotherapy},
  year = {2026},
  doi = {10.1177/10600280261500503}
}
Kostenlos starten →